Targeting sarcoma tumor-initiating cells through differentiation therapy.

Area of Science:

• Oncology
• Immunology
• Cancer Stem Cell Biology

Background:

• Down-regulation of Human Leukocyte Antigen class I (HLA-I) is linked to poor outcomes in various human cancers.
• The role of HLA-I in tumor-initiating cells (TICs) across different cancer types remains largely unexplored.

Purpose of the Study:

• To investigate the association between HLA-I expression and tumor-initiating capacity in human sarcomas.
• To characterize the molecular profiles and differentiation potential of HLA-I-negative TICs.
• To explore therapeutic strategies targeting HLA-I-negative TICs.

Main Methods:

• Flow cytometry and immunohistochemistry to assess HLA-I expression in sarcoma samples.
• In vitro cell culture and in vivo xenograft models to evaluate TIC properties.
• Gene expression analysis to identify molecular differences between HLA-I positive and negative cells.
• Treatment with all-trans retinoic acid (ATRA) to assess differentiation induction and anti-tumor effects.

Main Results:

• A subpopulation of sarcoma cells with high tumor-initiating capacity exhibited down-regulated HLA-I expression.
• These HLA-I-negative TICs displayed distinct molecular profiles related to proliferation, apoptosis, and stemness.
• TICs could be induced to differentiate into mesenchymal lineages, including osteogenic differentiation.
• The retinoic acid receptor signaling pathway was overexpressed in HLA-I-negative TICs.
• ATRA treatment promoted osteogenic differentiation of HLA-I-negative TICs in vitro and in vivo, significantly reducing tumor formation.

Conclusions:

• Down-regulated HLA-I is a common characteristic of TICs in diverse human sarcomas.
• Undifferentiated TICs can be targeted for differentiation therapy.
• Differentiation strategies, such as ATRA treatment, hold promise for inhibiting sarcoma tumor formation by targeting TICs.